Johnson & Johnson (NYSE:JNJ) Shares Sold by Fernwood Investment Management LLC

Fernwood Investment Management LLC decreased its holdings in Johnson & Johnson (NYSE:JNJ) by 2.3% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 13,284 shares of the company’s stock after selling 307 shares during the quarter. Fernwood Investment Management LLC’s holdings in Johnson & Johnson were worth $2,153,000 as of its most recent filing with the SEC.

A number of other large investors also recently modified their holdings of JNJ. BSW Wealth Partners raised its position in Johnson & Johnson by 2.2% in the third quarter. BSW Wealth Partners now owns 6,738 shares of the company’s stock worth $1,092,000 after acquiring an additional 143 shares in the last quarter. Angeles Wealth Management LLC raised its holdings in shares of Johnson & Johnson by 22.2% in the 3rd quarter. Angeles Wealth Management LLC now owns 15,837 shares of the company’s stock worth $2,567,000 after purchasing an additional 2,877 shares in the last quarter. Van ECK Associates Corp boosted its holdings in Johnson & Johnson by 12.7% during the third quarter. Van ECK Associates Corp now owns 780,186 shares of the company’s stock worth $129,401,000 after buying an additional 88,107 shares in the last quarter. GFS Advisors LLC grew its position in Johnson & Johnson by 33,557.6% in the third quarter. GFS Advisors LLC now owns 50,823 shares of the company’s stock worth $8,236,000 after buying an additional 50,672 shares during the last quarter. Finally, Latitude Advisors LLC increased its holdings in shares of Johnson & Johnson by 12.7% in the third quarter. Latitude Advisors LLC now owns 2,232 shares of the company’s stock valued at $362,000 after buying an additional 251 shares in the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson Stock Performance

Shares of JNJ stock opened at $160.13 on Monday. Johnson & Johnson has a fifty-two week low of $143.13 and a fifty-two week high of $168.85. The stock’s 50-day moving average is $163.31 and its two-hundred day moving average is $155.59. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79. The firm has a market cap of $385.53 billion, a P/E ratio of 23.17, a PEG ratio of 2.84 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, October 15th. The company reported $2.42 EPS for the quarter, topping analysts’ consensus estimates of $2.21 by $0.21. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. The firm had revenue of $22.47 billion for the quarter, compared to the consensus estimate of $22.17 billion. During the same quarter in the prior year, the company posted $2.66 earnings per share. The firm’s revenue was up 5.2% on a year-over-year basis. Analysts predict that Johnson & Johnson will post 9.94 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th will be given a dividend of $1.24 per share. The ex-dividend date is Tuesday, November 26th. This represents a $4.96 dividend on an annualized basis and a yield of 3.10%. Johnson & Johnson’s payout ratio is currently 71.78%.

Insider Buying and Selling at Johnson & Johnson

In other news, VP Robert J. Decker sold 5,635 shares of the business’s stock in a transaction on Friday, August 30th. The shares were sold at an average price of $165.06, for a total value of $930,113.10. Following the completion of the sale, the vice president now directly owns 18,973 shares in the company, valued at approximately $3,131,683.38. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 0.16% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on JNJ. Cantor Fitzgerald restated an “overweight” rating and issued a $215.00 target price on shares of Johnson & Johnson in a report on Wednesday, October 16th. Citigroup lifted their price target on Johnson & Johnson from $180.00 to $185.00 and gave the stock a “buy” rating in a research note on Wednesday, October 16th. Morgan Stanley raised their target price on shares of Johnson & Johnson from $169.00 to $175.00 and gave the stock an “equal weight” rating in a report on Wednesday, October 16th. Daiwa America lowered shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 23rd. Finally, StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, September 14th. Six analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $175.93.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.